Toren Finkel received his undergraduate degree in Physics and his MD and PhD degree from Harvard Medical School. Following a residency in Internal Medicine at the Massachusetts General Hospital, he completed a fellowship in Cardiology at Johns Hopkins Medical School. In 1992, after completing his clinical training, he came to the NIH as an Investigator within the Intramural Research Program of the National Heart, Lung and Blood Institute (NHLBI). Over the next 25 years at the NIH, he held various positions including Chief of the Cardiology Branch and Chief of the Center for Molecular Medicine within the NHLBI. He is a member of the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP). He has also been inducted as a Fellow of the American Association for the Advancement of Science (AAAS) and is an elected member of the National Academy of Medicine. He serves on numerous editorial boards including currently serving on the Board of Reviewing Editors for Science. As of Sept 1st 2017, Dr. Finkel assumed the role of the Director of the Aging Institute, and the G. Nicholas Beckwith III and Dorothy B. Beckwith Endowed Chair of Translational Medicine at the University of Pittsburgh/UPMC. Over the last three decades, his laboratory has made significant contributions in our understanding of the role of reactive oxygen species and mitochondrial function in aging and age-related diseases. He is also the co-founder of Generian Pharmaceuticals and Coloma Therapeutics, and with his colleagues, he has co-developed several small molecules which are anticipated to be in Phase I testing within 12 months and may be of potential benefit for a range of age-related disorders.